Department of Psychology, University of Wisconsin-Eau Claire, Eau Claire, WI, USA.
Department of Biological Sciences, University of Waikato, Hamilton, New Zealand.
Behav Brain Res. 2020 Feb 17;380:112369. doi: 10.1016/j.bbr.2019.112369. Epub 2019 Nov 17.
It is well accepted that opioids promote feeding for reward. Some studies suggest a potential involvement in hunger-driven intake, but they suffer from the scarcity of methodologies differentiating between factors that intersect eating for pleasure versus energy. Here, we used a unique food deprivation discrimination paradigm to test a hypothesis that, since opioids appear to control feeding reward, injection of opioid agonists would not produce effects akin to 22 h of food deprivation. We trained rats to discriminate between 22 h and 2 h food deprivation in a two-lever, operant discrimination procedure. We tested whether opioid agonists at orexigenic doses produce discriminative stimulus effects similar to 22 h deprivation. We injected DAMGO, DSLET, or orphanin FQ in the paraventricular hypothalamic nucleus (PVN), a site regulating hunger/satiety, and butorphanol subcutaneously (to produce maximum consumption). We assessed the ability of the opioid antagonist, naltrexone, to reduce the discriminative stimulus effects of 22 h deprivation and of the 22 h deprivation-like discriminative stimulus effects of PVN-injected hunger mediator, neuropeptide Y (NPY). In contrast to PVN NPY, centrally or peripherally injected opioid agonists failed to induce discriminative stimuli similar to those of 22 h deprivation. In line with that, naltrexone did not reduce the hunger discriminative stimuli induced by either 22 h deprivation or NPY administration in 2 h food-restricted subjects, even though doses used therein were sufficient to decrease deprivation-induced feeding in a non-operant setting in animals familiar with consequences of 2 h and 22 h deprivation. We conclude that opioids promote feeding for reward rather than in order to replenish lacking energy.
众所周知,阿片类药物促进进食以获得奖励。一些研究表明,它们可能参与了饥饿驱动的摄食,但这些研究受到区分愉悦进食和能量进食的因素的方法学的限制。在这里,我们使用独特的食物剥夺辨别范式来检验一个假设,即由于阿片类药物似乎控制着进食的奖励,因此注射阿片类激动剂不会产生类似于 22 小时食物剥夺的效果。我们训练大鼠在双杠操作性辨别程序中辨别 22 小时和 2 小时的食物剥夺。我们测试了食欲素剂量的阿片类激动剂是否会产生类似于 22 小时剥夺的辨别性刺激效应。我们在室旁核(PVN)中注射 DAMGO、DSLET 或孤啡肽 FQ,这是一个调节饥饿/饱腹感的部位,并且皮下注射丁丙诺啡(以产生最大消耗)。我们评估了阿片拮抗剂纳曲酮降低 22 小时剥夺的辨别性刺激效应和 PVN 注射饥饿介质神经肽 Y(NPY)的 22 小时剥夺样辨别性刺激效应的能力。与 PVN NPY 相反,中枢或外周注射的阿片类激动剂未能诱导类似于 22 小时剥夺的辨别性刺激。与此一致的是,纳曲酮并未降低 2 小时食物限制受试者中由 22 小时剥夺或 NPY 给药引起的饥饿辨别刺激,即使在熟悉 2 小时和 22 小时剥夺后果的动物中,在非操作性环境中使用的剂量足以减少剥夺诱导的进食。我们得出结论,阿片类药物促进进食以获得奖励,而不是为了补充缺乏的能量。